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Abstract
Skeletal metastasis is an important cause of mortality
in patients with breast cancer. Hence, animal mod-
els, in combination with various imaging techniques,
are in high demand for preclinical assessment of novel
therapies. We evaluated the applicability of flat-panel
volume computed tomography (fpVCT) to noninvasive
detection of osteolytic bone metastases that develop
in severe immunodeficient mice after intracardial in-
jection of MDA-MB-231 breast cancer cells. A single
fpVCT scan at 200-Mm isotropic resolution was em-
ployed to detect osteolysis within the entire skele-
ton. Osteolytic lesions identified by fpVCT correlated
with Faxitron X-ray analysis and were subsequently
confirmed by histopathological examination. Isotropic
three-dimensional image data sets obtained by fpVCT
were the basis for the precise visualization of the ex-
tent of the lesion within the cortical bone and for the
measurement of bone loss. Furthermore, fpVCT imag-
ing allows continuous monitoring of growth kinetics
for each metastatic site and visualization of lesions
in more complex regions of the skeleton, such as the
skull. Our findings suggest that fpVCT is a powerful
tool that can be used to monitor the occurrence and
progression of osteolytic lesions in vivo and can be
further developed to monitor responses to antimetas-
tatic therapies over the course of the disease.
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Introduction
The bone is the principal and frequent metastatic site in
patients with breast cancer and is the most common loca-
tion of the first relapse of this disease [1,2]. Many patients
with bone metastases suffer from severe bone pain, and
mortality is increased due to pathological fractures, nerve
compression syndrome, and hypercalcemia [3]. Tumor cells
invade bone cavities and secrete factors that stimulate osteo-
clasts to cause the resorption of cortical and trabecular bones.
Multiple interactions between metastatic cancer cells and osteo-
clasts are slowly being uncovered, providing novel targets to
design specific therapeutic interventions for bone metastases
[4,5]. To understand the molecular signature of cancers that is
specifically important to bone metastases and to preclinically
evaluate these novel targeted therapies, the development of
mouse models that mimic bone metastasis, in combination with
novel imaging techniques, remains a great challenge [6].
Intracardiac inoculation of a number of different tumor
types results in reproducible well-characterized bone metas-
tases in xenograft animal models [7]. One frequently used
model is based on the intracardial injection of MDA-MB-231
human breast cancer cells, consistently leading to bone but
not lung metastases within a few weeks [8]. A major limita-
tion in evaluating tumor progression in murine tumor models is
the inability to detect and monitor tumor metastasis in detail
over the course of the disease. The study of bone metastasis
in small animal models has frequently only relied on rather
cumbersome histologic analyses at the end of the study.
Sacrifice of animals limits the evaluation of metastatic spread
to a single time point instead of permitting individual lesions
to be followed over time. In vivo detection of bone metasta-
ses using high-resolution radiographic analysis has been
used in an attempt to provide temporal information. However,
classic osteolytic lesions associated with significant bone de-
struction can be detected by current radiography only at
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advanced stages, thereby leading to underestimation of the
number and extent of bone metastases.
Serial micro–computed tomography (micro-CT) analysis
has been used to investigate the effect of metastases on
bone microarchitecture and bone strength [9–11]. Mag-
netic resonance imaging (MRI) has also shown potential
to identify bone marrow metastases in mice before the de-
velopment of cortical bone loss identifiable by X-ray [12,13].
Furthermore, nuclear medicine bone scans [14,15], skeletal
scintigraphy [12], and new imaging modalities based on
the optical detection of reporter genes that are biolumines-
cent [16] or fluorescent [17] promise to detect early events
of bone metastases and to improve throughput and quanti-
fication accuracy in metastatic animal models.
In the present study, we evaluated the utility of a novel
imaging technique, flat-panel volume computed tomography
(fpVCT), to discover and monitor the osteolytic bone metas-
tases of MDA-MB-231 cells in severe combined immunode-
ficient (SCID) mice in vivo over time. We demonstrate that
fpVCT allows accurate localization, size determination, and
assessment of the progression of lesions within the mouse
skeleton, enabling rapid noninvasive detection and longitu-
dinal monitoring of osteolytic bone lesions.
Materials and Methods
Breast Cancer Cells
The estrogen-independent human breast cancer cell line
MDA-MB-231 was obtained from the American Type Culture
Collection (Rockville, MD) and was cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf
serum and 1% L-glutamine (all from PAN Systems, Aiden-
bach, Germany) in a humidified atmosphere of 5%CO2 in air.
Cells were regularly certified as free of Mycoplasma con-
tamination. Cells were harvested to near-confluence by
incubation with a 5-mM Na-EDTA solution (Gibco, Carlsbad,
CA), washed several times, and placed in sterile phosphate-
buffered solution shortly before implantation.
Animals
All animals were maintained under pathogen-free condi-
tions and handled according to German regulations for ani-
mal experimentation approved by the administration of Lower
Saxony, Germany. All manipulations were conducted under
aseptic conditions using a laminar flow hood. For this study,
SCID mice (strain C.B-17/Ztm-scid ) were used. Immunodefi-
ciency of SCID mice was verified by measuring serum immu-
noglobulin levels with enzyme-linked immunosorbent assay.
Intracardiac Experimental Metastasis Model
Six- to 10-week-old (n = 14) and 4- to 6-month-old
female SCID mice (n = 7) were anesthetized with an intra-
peritoneal injection of 75 mg/kg ketamine hydrochloride with
15 mg/kg xylazine. Mice were injected with either 1  105 or
5  105 MDA-MB-231 cells suspended in 100 ml of sterile
PBS through the intercostal space into the left ventricle of
the heart using a 19-gauge needle.
Detection of Osteolytic Bone Lesions By fpVCT
Assessment of subsequent metastasis was monitored by
fpVCT (GE Global Research, Niskayuna NY) either in vitro, by
imaging isolated skeletal bones of dissected mice, or in vivo,
by monitoring six anesthetized mice after the inoculation of 1 
105 MDA-MB-231 cells over time on days 16, 23, 30, 37, and
43. An additional scan on day 6 and a last scan on day 42
were performed with mice after the inoculation of 5 105 cells.
For this purpose, mice were anesthetized with vaporized
isoflurane at 1.5% to 2% concentration throughout an imag-
ing session, centered on the fpVCT gantry axis of rotation, and
placed perpendicular to the z-axis of the system, so that it was
possible to scan the whole mouse with one rotation. fpVCT
consists of a modified circular CT gantry and two amorphous
silicon flat-panel X-ray detectors, each of 20.5  20.5 cm2 with
a 1024  1024 matrix of 200-mm detector elements. fpVCT
works with a step-and-shoot acquisition mode. The standard
z-coverage of one step is 4.21 cm. This system allows the
acquisition of real isotropic volume data sets with a resolution
of about 150 to 200 mm for high-contrast structures such as
bones. All data sets were acquired with the same protocol:
1000 projection images per rotation, 8-second rotation time,
360 used detector rows, 80 kVp, and 100 mA. A modified
Feldkamp algorithm implemented on an eight-node simulta-
neous computer was used for image reconstruction resulting
in high-resolution volume data sets (512  512 matrix), which
were analyzed with voxtools 3.0.64 AdvantageWorkstation 4.2
(GE Healthcare, Buckinghamshire, UK). To suppress digitali-
zation artifacts, the isotropic voxel size of reconstructed vol-
ume data sets was about 100 mm less than the resolution of
the system. Mice were sacrificed at the end of the 6-week ob-
servation period, and bones containing osteolytic lesions were
dissected and analyzed by Faxitron analyses and histology.
Detection of Osteolytic Bone Lesions By Radiography
and Histology
To confirm the presence of osteolytic lesions, radiographs
of either isolated legs or dissected mice were taken using
Faxitron (Faxitron model 43855; Hewlett Packard, Palo
Alto, CA), with the following parameters: 36 kV, 0.3 mA of
tube current, and 6 minutes of exposition. For histologic
analysis, the legs of dissected mice were either embedded
in methylmethacrylate as described before [18] or decalcified
in Na-EDTA and processed for paraffin embedding. Five-
micrometer serial sections were obtained and stained with
hematoxylin and eosin (H&E).
Results
Detection of Osteolytic Lesions By Radiographic
Techniques and Histology In Vitro
To detect tumor osteolysis in our initial experiments, limb
bones were dissected from eight mice following the inocula-
tion of 5  105 MDA-MB-231 cells in the left ventricle for
28 days. Imaging with fpVCT demonstrated the presence
of distinct radiolucent osteolytic lesions in the distal femur,
proximal tibia, and proximal humerus in three of eight mice
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(Figure 1, A and E ). The presence of these osteolytic lesions
was confirmed by Faxitron X-ray analysis, which revealed
tumor-induced bone lesions as radiolucent foci (Figure 1, B
and H ). To rule out that a process other than metastatic
growth of tumor cells caused these osteolytic lesions, histo-
logic examination was used to verify the presence of tumor
cells precisely at the location of radiolucent skeletal elements
(Figure 1, C and D) and to confirm the destruction of the
corticalis by invading tumor cells (Figure 1, F and G ).
Progressive Formation of Osteolytic Lesions within
Complex Bone Structures In Vivo over Time
To monitor the onset and progression of bone lesions
over time, six mice were inoculated intracardially with 1 
Figure 1. Detection of an osteolytic lesion after intracardial implantation of MDA-MB-231 cells. (A) Volume rendering of a distal humerus with fpVCT 28 days after
tumor cell injection demonstrates an osteolytic lesion within the cortical bone (white arrow). (B) Confirmation of the findings (white arrow) by standard radiographic
examination with Faxitron X-ray. (C and D) A representative histologic section stained with H&E confirmed the presence of mammary carcinoma cells in the bone
cavity with cortical destruction. Tumor cells infiltrate the bone cavity and replace hematopoiesis (black arrows). (E) Volume rendering of a 3D data set of a dissected
proximal tibia embedded in methylmethacrylate with complete destruction of the corticalis (arrow). (F and G) H&E staining of the histologic section confirms the
destruction of the corticalis by invading tumor cells. (H) Comparable depiction of osteolysis (arrow) with Faxitron analysis. The length of the bar in (A) represents
4 mm: 800 m (C) and 200 m (D).
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105 MDA-MB-231 cells, and sevenmice were inoculated with
5  105 MDA-MB-231 cells.
Anesthetized animals were monitored with fpVCT within
8 seconds at several time points to identify osteolytic lesions
within the entire skeleton. In vivo analysis of the presence
and progress of tumor osteolysis revealed that even in the
complex anatomic structure of the skull (Figure 2, A–D),
osteolytic lesions could be visualized by high-resolution
three-dimensional (3D) fpVCT imaging demonstrating a high
anatomic detail of bone structures. Because structures of low
density are present even in the normal skull, only a compar-
ison of fpVCT images with scans taken on day 6 of the study
confirmed that the skeletal alterations observed in the skull
have developed over time and are, therefore, most likely
caused by metastases within the occipital area (Figure 2, C
andD). In contrast, Faxitron analysis on the day of dissection
showed projectional overlap of various bone structures and
was, therefore, not able to detect osteolytic lesions within the
complex skull structure (Figure 2, E and F).
Of six mice inoculated with 1  105 MDA-MB-231 cells,
osteolytic lesions were detected either in the tibia or in the
humerus of three mice. Four mice of the second group, which
Figure 2. Detection of osteolytic lesions within the skull in vivo over time. (A and B) The presence of osteolytic lesions within the skull (white arrows) is depicted
by noninvasive imaging with fpVCT from the time of the intracardial inoculation of MDA-MB-231 cells. (C and D) A higher magnification of the same area of the skull
clearly depicts, after 42 days (white arrows), two radiolucent areas within the occipital bone of a SCID mouse that are not visible on an fpVCT image after 6 days.
The (E) lateral and (F) dorsal views of the 2D radiogram of a Faxitron analysis of the same mouse dissected after 42 days depict no bone lesion within the complex
anatomic structure of the skull. The lengths of the bars in (A) and (B) represent 4 mm (C) and (D) 2 mm.
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were inoculated with 5  105 MDA-MB-231 cells, showed
osteolytic lesions in the skull, in the distal humerus, or in the
proximal tibia/knee.
Monitoring of the Development and Progression of
Osteolytic Lesions
To noninvasively assess the progression of osteolytic
lesions, fpVCT images of the whole skeleton of anesthetized
mice were taken at distinct time points within 8 seconds.
Axial images, as well as multiplanar reconstruction and
volume-rendering images, were obtained to exhibit lesions
on the bone surface, as well as the extension of osteolysis.
A semitransparent volume-rendering image displayed pre-
cisely the corticalis of the tibia and, therefore, allowed the
assessment of the integrity of the corticalis (Figure 3). 3D
images of fpVCT data sets revealed that 23 days after
intracardial inoculation of MDA-MB-231 cells, a small bone
defect can be depicted in the metaphyseal region of the
proximal tibia of the living mouse (Figure 3B), in comparison
to day 16 when only a minor corticalis defect was visible
at that site (Figure 3A). Progression of the osteolytic lesion
was observed on days 30, 37, and 43, when the corticalis
defect becomes more visible (Figure 3, C–E ). After day 30,
the osteolytic lesion had expanded and destroyed large
parts of the corticalis (Figure 3D). Finally, the enlarged
osteolytic bone metastasis is delineated within the proximal
tibia (Figure 3E ). The corresponding conventional radio-
graph of the tibia of the dissected mouse on day 43 con-
firmed the presence of the osteolytic lesion (Figure 3F ).
From fpVCT data sets, maximum intensity projection can be
generated in each orientation. These images are, therefore,
comparable to conventional radiography images, which are
most advantageous for visualizing metastases involv-
ing surface-elongated bones (Figure 3G). Two-dimensional
(2D) visualization of a slice through the osteolytic lesion by
fpVCT confirmed massive bone lysis with corticalis destruc-
tion on day 43.
In contrast to the presentation of radiolucent foci by
conventional radiographs, 3D data sets of an fpVCT image
allow visualization of the bone lesion in infinitely variable
angles (Figure 4, A–D). Thus, the extension of bone de-
struction within the cortex of the compact bone can be
assessed. As shown in Figure 4D, the osteolytic lesion has
destroyed the corticalis of the lateral and inner sites of the
proximal tibia, resulting in an extensive cavity within the
bone. The high-resolution volume data sets obtained by
fpVCT are superior to Faxitron analysis because they can
be used to generate virtual tomographic sections through the
tibia with a thickness of < 200 mm in all desired orientations.
Thus, the entire extension of the lesion within the bone can
be assessed and revealed that only a small intact margo
anterior is left (Figure 4,E–H ). In contrast, standard Faxitron
analysis only allows visualization of the bone in a very limited
number of planes because isolated bones or mice can only
Figure 3. Longitudinal study of the development and progression of an osteolytic lesion within the tibia of a SCID mouse. Representative fpVCT 3D images of
the tibia of a SCID mouse at distinct time points from the time of the intracardial inoculation of MDA-MB-231 cells are shown (A) after 16 days, when a minor
bone defect is visible; (B) after 23 days, when a small bone lesion can be depicted in the tibia (arrow); (C) after 30 days, when an osteolytic lesion with a small
corticalis defect is illustrated (arrow); (D) after 37 days, when the osteolytic lesion expands and completely destroys the corticalis; and after (E) 43 days, when the
enlarged osteolytic bone metastasis is delineated within the tibia. Note that the corticalis is depicted as a red shaded line. (F) A corresponding conventional
radiograph of the tibia of the dissected mouse on day 43 confirmed the presence of the osteolytic lesion (arrow). (G) Maximum intensity projection of the fpVCT
scan on day 43 showed similar image content such as Faxitron. (H) 2D visualization of a slice through the osteolytic lesion by fpVCT. The length of the bar in
(A) represents 4 mm.
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be placed at limited positions, as much as possible parallel to
the X-ray film to avoid a reduction in resolution.
Assessment of the Extension and Growth Rate of the
Osteolytic Lesion over Time By fpVCT Imaging
High-resolution imaging by fpVCT allows measurements
of distances with a precision of 200 mm in two dimensions of
the osteolytic lesion within the tibia and, therefore, assess-
ment of the growth rate and dimension of the destroyed bone
area from the time of tumor implantation. Because the
compact bone is completely destroyed in the third dimen-
sion, only the surface area of the bone lesion can be
determined. The developing osteolytic cavity within the prox-
imal tibia leads to two distinct apertures: one on the inner site
and one on the lateral site of the tibia. As shown in Figure 5,
the area of destroyed bone surface on the lateral site of the
right tibia increased from 0.070 to 0.118 mm2 on days 30 to
37 and was more than double in size 1 week later, with an
area of 0.251 mm2. The osteolytic aperture of the inner site
of the tibia was visualized first on day 37 with an area of
0.079 mm2 and increased exponentially 1 week later on day
43 to a size of 0.141 mm2.
Furthermore, virtual tomographic sections were used to
view bone defects from the inside of the bone (Figure 5, G
and H ), allowing 2D measurements of the area of bone
destruction. By doing so, the full extension of the osteolytic
lesion during tumor progression could be assessed. Both
osteolytic lesions in the corticalis of the tibia that become
manifest outside of the tibia extend nearly exponentially,
although aperture on the left side appeared earlier.
Measurement of the diameters of the corticalis in cross
sections of the fpVCT images of the affected right tibia at the
same distance to the knee over time revealed not only bone
and corticalis defects at the metastatic site but also reduced
thickness of the corticalis (0.1 mm) at the opposite site after
43 days in comparison to day 16 (Figure 6, A and B). This
demonstrates that tumor cells have already extended to
within the medulla of the tibia and have affected other parts
of the bone that are not as visible as osteolytic lesions. In
comparison, the healthy left tibia showed no alteration in
corticalis thickness at the same time points and in the same
locations (Figure 6, C and D).
Changes in Bone Mass and Density Ratios of the
Tibia over Time
To precisely assess the degree of damage, and hence
loss of bone mass, caused by metastasis, we automatically
analyzed total bone volumes at different time points by
virtually isolating both tibias from fpVCT data sets. The
increasing total volumes of the tibias due to the growth of
mice over time were corrected under the assumption that the
volume of the left tibia is constant, with a total bone volume of
36.55 mm3. As shown in Figure 7A, the total bone volume of
the tumor-burdened right tibia decreases progressively by
about one third over 27 days (from 39.98 to 26.71 mm3),
whereas the volumes of the left tibia remained unchanged
over time.
Histograms generated from fpVCT data sets of the seg-
mented tibia with the osteolytic lesion represent the percent-
age of the total volumes of the tibia versus its measured
Figure 4. Evaluation of the osteolytic lesion in arbitrary planes and virtual sections by fpVCT imaging. Representative 3D data sets of the fpVCT images of the tibia
of a SCID mouse 43 days after intracardial injection of MDA-MB-231 cells allow the visualization of the osteolytic lesion within the tibia in infinitely variable angles
(A–D). (E) The bone surface shows a distinct lesion with an intact margo anterior. (F–H) The entire extension of the bone lesion can be assessed by virtual slices
through the destroyed corticalis toward the bone cavity. It seems that the bridge of the margo anterior prevents the bone from being fractured. The length of the bar
in (A) represents 4 mm.
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Figure 5.Monitoring of the growth rate of the osteolytic cavity over time by fpVCT imaging. High-resolution imaging by fpVCT allows measurements of distances in
two dimensions of the osteolytic lesion within the tibia from the time of tumor implantation. (A) Right lateral view of the tibia and (B) left lateral view of the tibia after
30 days; (C) right lateral view of the tibia and (D) left lateral view of the tibia after 37 days; (E) right lateral view of the tibia and (F) left lateral view of the tibia after
43 days. (G and H) Virtual sections applied to a volume-rendering fpVCT image of the tibia allow the measurement of distances in two dimensions within the bone
lesion. (G) View from the bone marrow to the wall of the corticalis, and (H) frontal section through the osteolytic cavity in a left lateral view, both images after
43 days. The length of the bar in (A) represents 1 mm.
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densities in Hounsfield units (HU) at two time points (Fig-
ure 7, C and D). Quantitative distribution of densities within
the tibia volume can be depicted. High-density bone is rep-
resented by > 1500 HU, whereas regions of low density
represent the medulla, which is composed of a network of
trabecular structures.
The histogram of day 16 is composed of two underlying
distributions of different density portions, which represent the
corticalis region and the region of the medullary cavity
composed of trabecular structures (Figure 7C). On day 43,
the alteration of the histogram clearly depicts a loss of the
high-density portions of the bone, with a simultaneous in-
crease in bone material with density lower than that of the
corticalis, suggesting partial resorption of the corticalis (Fig-
ure 7, C and D) and corresponding to our findings that wide-
ranging degradation toward the inner corticalis takes place
as shown in Figure 6. The loss of volume of the entire tibia
bone mass corresponding to the extending osteolysis of the
inner corticalis (Figure 6, A and B) is in accordance with the
declining area of the histogram. This comparative analysis of
histograms at two time points clearly shows that bone lesion
progresses by destroying corticalis structures.
Discussion
In this study, the utility of a novel method to noninvasively
analyze metastatic spread to the skeleton is shown by ap-
plying experimental volume CT with flat-panel detectors to
the common bone metastasis model that requires intracardial
inoculation of human MDA-MB-231 estrogen-independent
breast cancer cells. Noninvasive methods are needed pre-
clinically to understand tumor biology and to evaluate anti-
metastatic therapy for bone metastases that are often
associated with breast cancer.
We could show that high-resolution 3D imaging allows
detailed visualization of the mouse skeleton and, therefore,
shows excellent sensitivity in detecting skeletal lesions at the
osteolytic stage of the disease. Bones can be well depicted
by fpVCT even without contrast media because of their
favorable contrast properties. Therefore, fpVCT allows, in
short scan times of 8 seconds, the imaging of the whole
skeleton of mice and, hence, accurate anatomic localization
of osteolytic lesions within the metaphyseal and diaphyseal
cortical bones of the lower and upper legs, as well as in
regions of the skeleton such as the skull in which lesions can
hardly be visualized by standard Faxitron analysis. In the
latter, isolated bones of mice can only be placed at certain
positions to the X-ray film. Therefore, visualization of the
bone is limited to a low number of planes, and overlap of
bone structure occurs frequently.
Unlike radiography, fpVCT is a rapid and cost-effective
imaging method that provides 3D representation in which
bone structures are better visualized without projectional
overlap. MRI has been shown to delineate the tumor itself
Figure 6. Assessment of the osteolytic lesion and of the corticalis within the tibia. Representative cross sections of the fpVCT images of both tibias from the time of
tumor cell injection. Measurements of the diameters of the corticalis of the (A) right tibia and the (C) left tibia on day 16, in comparison to the (B) corticalis of the right
tibia with an osteolytic lesion and the (D) left tibia on day 43. Note the corticalis defect and the decreased diameters of the corticalis on day 43 in comparison to
day 16. The length of the bar in (A) represents 2 mm.
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within the bone cavity [12,13,19]. Both fpVCT and radiogra-
phy are only able to detect tumor metastases on loss of
mineralized tissues in response to tumor-induced osteolysis.
In contrast, MRI has been used to depict tumor progression
directly within the bone marrow cavity [12,13]. Furthermore,
optical imaging with fluorescently labeled antibodies has
successfully been applied for the early detection of tumor
cells at the site of metastasis within the bone. As an exam-
ple, it was shown that fluorescence imaging of live animals
allowed the detection of the intramedullary tumor growth
of green fluorescent protein– labeled cells approximately
1 week before the occurrence of radiologically distinct osteo-
lytic lesions [19]. Similarly, luciferase-transfected cells, in
combination with whole-body bioluminescent imaging, were
used to detect microscopic bone metastases of approxi-
mately 0.5 mm3 [16,17,20].
In contrast, fpVCT is of great advantage in monitoring
the extent of osteolytic lesions. Compared with optical im-
aging and MRI, fpVCT has a much better 3D resolution,
especially for high-density structures, and thus provides
the ability for a more accurate assessment of the extent of
bone destruction.
Another method performed to evaluate bone metastases
is skeletal scintigraphy using [99mTc]methylene diphosphate,
which mimics calcium phosphate then becomes incorporated
into regions of active bone turnover [13]. However, in small
animals, this method has a relatively poor spatial resolution
compared to fpVCT. Nuclear medicine bone scans are also
sensitive to detecting osteoblastic bone metastases but may
miss small lesions with diameters of < 1 cm3 and may lack
specificity [14,21].
The delineation of the anatomic details of bone structures
in mice has been previously described for fpVCT imaging
[22–25], as well as for micro-CT [26]. Micro-CTwas also used
to visualize experimental multiple bone metastases in the
intact living mouse with serial long scanning times of about
12 minutes. Therefore, micro-CT, in comparison to fpVCT, is
more invasive with respect to radiation dose and anesthesia,
and is more susceptible to motion artifacts [9,10]. However,
due to its high resolution of V 50 mm, micro-CT is superior
to fpVCT in the evaluation of fine trabeculae structure and
microarchitecture [27]. In this study, we could demonstrate
that the 200-mm resolution of fpVCT is sufficient to detect
minor bone lesions in various areas of the skeleton.
It has been standard practice to monitor bone metastases
using conventional radiography and bone histomorphometry
performed at the end of the experiments. Histologic analy-
sis performed to search for metastases within the whole
Figure 7.Measurement of total bone volumes and the density ratios of the tibia over time. (A) The diagram shows the decrease of the total bone volume of the right
tibia containing the bone lesion (black bars) in comparison to the left tibia (white) over time, 16, 37, and 43 days after the implantation of MDA-MB-231 cells. (B)
Volume-rendering representation of the right and left tibiae scanned with fpVCT on day 43. A massive bone defect is depicted in the right tibia (circle). (C and D)
Histograms of X-ray attenuation distributions are displayed and measured in Hounsfield units for the segmented right tibias (C) on day 16 and (D) day 43. (C) A
typical graph seen in the histogram of the tibia at the early time point is the result of the summation of underlying distributions for the bone marrow with a low density
(< 500 HU), with the region of the medullary cavity composed of trabecular structures (red curve), and the corticalis region (white curve) with a high density. (D)
Overlay of the histogram on day 16 (yellow) and the histogram 1 day before dissection (blue). At the time when tumor osteolysis occurs, loss of bone mass, which
can be determined exactly, is illustrated in a slight reduction of low-density portions (most likely representing the bone marrow) (white arrow) caused by invading
tumor cells. In comparison to the early time point, the graph of the histogram on day 43 (the clear distribution of the compartments of the corticalis and the
trabecular structures) becomes indistinct as result of an increase in bone with medial density (green arrow) and a decrease in bone with high density (orange
arrows), suggesting that the bone lesion progresses by destroying corticalis structures.
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skeleton is typically difficult and extremely laborious. There-
fore, imaging methods performed to determine osteolytic
lesions are highly desirable. In comparison to standard
Faxitron X-ray, fpVCT is superior because it obtains true
isotropic 3D volume data sets to evaluate the skeleton in
arbitrary planes and in virtual tomographic sections. Visual-
ization of bone lesions and virtual cross sections with a
thickness of 200 mm from various angles, as well as from
inside the bone, permits the assessment of the complete
extension of the osteolytic lesion by viewing the defect from
the inner or the outer site of the bone. Furthermore, vari-
ous 3D visualization techniques can be applied to fpVCT
data sets, such as semitransparent volume rendering and
maximum intensity projection. This allows a precise analy-
sis of the osteolytic lesion within the corticalis or gaining
of information on the exact location of the lesion within
the bone.
Another advantage of fpVCT is the chance to repeat it
several times in vivo and, therefore, to monitor tumor burden
in the bone of living animals throughout the course of the
experiment. When evaluating therapeutic efficacy, fpVCT
might allow to identify and use only the subset of animals
that had developed bone lesions, as well as to follow an
individual lesion longitudinally. Due to precise measure-
ments in two dimensions of the area of bone destruction at
any time, the onset and progression of the bone destruction
of individual bone lesions might be accurately assessed over
the course of the disease. In clinical settings, monitoring me-
tastatic bone lesions by fpVCT will provide a timely and
precise measurement of the efficacy of antineoplastic ther-
apy. Closely following tumor progression or tumor relapse is
imperative for a tailored therapeutic strategy.
Measurements of corticalis thickness in cross sections
allow the characterization of the extension of the destroyed
bone mass by invading tumor cells. Our results clearly show
that loss of bone mass is not only restricted to the osteolytic
lesion itself but also affects the whole inner corticalis. Fur-
thermore, with the ability to analyze the total volume of sin-
gle bones automatically in fpVCT data sets, changes in
bone mass, and hence the destruction of the whole bone
caused by osteolysis, can be precisely and semiautomati-
cally determined over time. Histograms of bones generated
over time offer information on the distribution of bones
containing dense portions and display bone volume as
represented by the area below the curve at one time point.
Changes in portions according to loss of specific bone
structures such as the corticalis or medulla, as a conse-
quence of the wide-ranging loss of bone mass, are exactly
educible and will allow an understanding of the extent of
tumor progression.
In summary, fpVCT may be a powerful and cost-effective
tool for detecting osteolytic lesions within the skeleton of
mice and for monitoring bone response to tumor cells in vivo
over time. By assessing the precise localization and size of
bone lesions in a longitudinal study, fpVCT might be applied
to clinically evaluate response to antimetastatic therapies
over the course of the disease and might help to optimize or
change therapeutic strategy at an early stage.
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